Sign in
MPLT Stock Price, Chart, Stats & News
MapLight Therapeutics, Inc.
Save
23.06M
Market cap
–
Current P/E
–
Forward P/E
MPLT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -33.61% |
ROE | -75.96% |
D/E | 0.01x |
Interest coverage ratio | – |
MPLT valuation
P/E | – |
P/S | – |
P/B | 1.78x |
P/CF | -5.91x |
P/FCF | -0.11x |
P/OCF | -5.91x |
PEG | 0.10x |
EV multiple | -0.33x |
About
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease.
Similar securities
Based on sector and market capitalization
Report issue